A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

ClinicalTrials.gov ID: NCT06330064

Public ClinicalTrials.gov record NCT06330064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Study identification

NCT ID: NCT06330064
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 520 participants

Conditions and interventions

Conditions

Recurrent or Metastatic Solid Tumors

Interventions

Ifinatamab deruxtecan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 9, 2024
Primary completion: Jul 24, 2028
Completion: Jul 24, 2028
Last update posted: Feb 11, 2026

2024 – 2028

United States locations

U.S. sites: 17
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
Los Angeles Cancer Network	Los Angeles	California	90017	Recruiting
Valkyrie Clinical Trials	Los Angeles	California	90067	Active, not recruiting
Pih Health Hematology Medical Oncology	Whittier	California	90602	Recruiting
Orchard Healthcare Research Inc.	Skokie	Illinois	60077	Recruiting
M Health Fairview University of Minnesota Medical Center	Minneapolis	Minnesota	55455	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Icahn School of Medicine At Mount Sinai Prime	New York	New York	10029	Recruiting
Clinical Research Alliance	Westbury	New York	11590	Recruiting
Tn Gynecologic Oncology Group, Llc	Chattanooga	Tennessee	37403	Recruiting
The West Clinic	Germantown	Tennessee	38138	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Texas Oncology - West Texas	Amarillo	Texas	79124	Recruiting
Texas Oncology, P.A.	Dallas	Texas	75246	Recruiting
Texas Oncology Gulf Coast	Pearland	Texas	77584	Recruiting
University of Utah Hospitals & Clinics	Salt Lake City	Utah	84108	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Wenatchee Hospitals and Clinics	Wenatchee	Washington	98801	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06330064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 11, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06330064 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →